Seroprevalence of SARS-Cov-2 Antibodies in Children
1 other identifier
observational
1,100
1 country
5
Brief Summary
It is unknown what proportion of healthy children have been exposed to SARS-Cov-2 and how many have antibodies. The aim of this study is to follow a cohort of healthy children over six months and measure their antibodies to SARS-CoV-2.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2020
Typical duration for all trials
5 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 7, 2020
CompletedFirst Posted
Study publicly available on registry
April 15, 2020
CompletedStudy Start
First participant enrolled
May 6, 2020
CompletedResults Posted
Study results publicly available
August 18, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
November 14, 2023
CompletedDecember 7, 2023
November 1, 2023
1.6 years
April 7, 2020
August 10, 2021
November 14, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Immunoglobulins (G and M) to SARS-Cov2 in Plasma
• Mean antibody titres (IgG/Total antibody) to SARS-CoV-2 in plasma using ROCH/ABBOTT and DIASORIN assays
6 months
Secondary Outcomes (3)
Echocardiogram Ejection Fraction
6 months
High-sensitivity Cardiac Troponin Test
6 months
Brain Natriuretic Peptide
6 months
Study Arms (3)
Healthy Children
Healthy children of healthcare workers between 2 and 15 years of age
Paediatric Multisystem Inflammatory Syndrome
Children admitted to hospital with Paediatric Multisystem Inflammatory Syndrome
Serious Infection
Children admitted to hospital with serious infections
Interventions
Antibody testing for previous exposure to Covid-19
Storage of blood for multi-omics analysis
Eligibility Criteria
Children aged from 0 to 15 who are resident in the United Kingdom
You may not qualify if:
- Not currently receiving antibiotics, not admitted to hospital within the last seven days, not receiving immunosuppressive drugs and never diagnosed with a malignancy.
- Admitted children with paediatric multisystem inflammatory syndrome and admitted children with other serious infections.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Queen's University, Belfastlead
- Belfast Health and Social Care Trustcollaborator
Study Sites (5)
Royal Belfast Hospital for Sick Children
Belfast, BT126BA, United Kingdom
University Hospital of Wales
Cardiff, United Kingdom
Royal Hospital for Children
Glasgow, United Kingdom
Public Health England
London, United Kingdom
Public Health England
Manchester, United Kingdom
Related Publications (1)
Waterfield T, Watson C, Moore R, Ferris K, Tonry C, Watt A, McGinn C, Foster S, Evans J, Lyttle MD, Ahmad S, Ladhani S, Corr M, McFetridge L, Mitchell H, Brown K, Amirthalingam G, Maney JA, Christie S. Seroprevalence of SARS-CoV-2 antibodies in children: a prospective multicentre cohort study. Arch Dis Child. 2021 Jul;106(7):680-686. doi: 10.1136/archdischild-2020-320558. Epub 2020 Nov 10.
PMID: 33172887DERIVED
Biospecimen
Plasma
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Limitations and Caveats
The limitations of this study are that all of the children in this study had only mild disease making comparison between severe and mild disease impossible. The children were also recruited from healthcare workers and the prevalence of antibodies is likely to be lower in the general population.
Results Point of Contact
- Title
- Dr Thomas Waterfield
- Organization
- Queen's University Belfast
Study Officials
- PRINCIPAL INVESTIGATOR
Thomas Waterfield, BMBCh
Queen's University, Belfast
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- No
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Chief Investigator and Academic Clinical Lecturer
Study Record Dates
First Submitted
April 7, 2020
First Posted
April 15, 2020
Study Start
May 6, 2020
Primary Completion
December 1, 2021
Study Completion
November 14, 2023
Last Updated
December 7, 2023
Results First Posted
August 18, 2021
Record last verified: 2023-11